An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients With Advanced Adenocarcinoma

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

Start Date14 Jul 2023

Sponsor / Collaborator

BioAtla, Inc.

NCT05271604 / RecruitingPhase 2

A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Start Date13 Dec 2022

Sponsor / Collaborator

BioAtla, Inc.

NCT05180799 / RecruitingPhase 1/2

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors

Start Date03 Aug 2022

Sponsor / Collaborator

BioAtla, Inc.

100 Clinical Results associated with BioAtla, Inc.

0 Patents (Medical) associated with BioAtla, Inc.

Literatures (Medical) associated with BioAtla, Inc.

01 Jun 2024·Journal of Clinical Oncology

Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.

Author: Kwatra, Vineet ; de Souza, Paul L. ; Albany, Costantine ; Aysola, Kartik ; Mehmi, Inderjit ; Thomas, Jacob Stephen ; Selfridge, Jennifer Eva ; Llorin-Sangalang, Judith Dubal ; Taylor, Matthew H. ; Hu-Lieskovan, Siwen ; Hamid, Omid

2602 Background: Immune checkpoint inhibition of cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) in combination with programmed cell death protein 1 (PD-1) has demonstrated durable clinical benefit in patients with advanced solid tumors. However, dose density is limited due to toxicity. BA3071 is a conditionally active biologic (CAB) anti–CTLA-4 monoclonal antibody that blocks the interaction of CTLA-4 with its ligands CD80 and CD86 [1]. CABs are activated within the acidic tumor microenvironment. Conditional and reversible binding of BA3071 may reduce on- and off-tumor immune-related adverse events (AEs) and autoimmunity, avoid tissue-mediated drug deposition, and improve pharmacokinetics. We evaluated the safety and antitumor activity of BA3071 in patients with advanced solid tumors. Methods: Patients naïve to anti–CTLA-4 therapy with advanced solid tumors received escalating doses of single-agent BA3071 every 3 weeks (Q3W) at cycle 1, followed by combination BA3071 + nivolumab from cycle 2 onward. Treatment continued until disease progression or unacceptable toxicity. Response assessment was performed Q6W with RECIST v1.1. Results: Eighteen patients were treated with BA3071 (7–700 mg) and nivolumab (240 mg); 61% had received ≥3 lines of prior systemic therapy, and all patients had experienced failure of anti–PD-1 therapy. Four patients experienced grade 3 related treatment-emergent AEs (TEAEs; hypertension, increased lipase, atrial fibrillation, gastritis, and diabetic ketoacidosis); no grade 4 related TEAEs were observed. Two patients experienced grade 3 immune-related TEAEs (diarrhea [BA3071 350 mg] and diabetic ketoacidosis [BA3071 700 mg]). Among 16 efficacy-evaluable patients, 9 experienced stable disease, and 2 out of 5 patients receiving BA3071 in the 350-mg cohort achieved confirmed RECIST v1.1 responses (complete response in cervical carcinoma and partial response in gastroesophageal carcinoma). One patient with metastatic small cell lung cancer who received 7 mg BA3071 remained without progression for >1 year (69 weeks). Conclusions: Treatment with the novel, conditionally active anti–CTLA-4 agent BA3071, in combination with anti–PD-1 therapy (at doses higher than those currently approved for anti–CTLA-4/PD-1 therapy), yielded confirmed responses with a promising tolerability profile. Phase 1 dose escalation of BA3071 continues at 700 mg up to 1000 mg, and phase 2 monotherapy and combination therapy expansion cohorts are currently enrolling at a starting dose level of 350 mg. 1. Chang HW et al. Proc Natl Acad Sci USA.2021;118(9):e2020606118. Clinical trial information: NCT05180799 .

01 Jun 2023·Journal of Clinical Oncology

Population pharmacokinetic and exposure-response safety analyses of mecbotamab vedotin (BA3011) in patients with advanced solid tumors.

Author: Baker, Michael G. ; Boyle, William J. ; Briggs, Emily ; Shen, Guoxiang George ; Crass, Ryan ; Karumanchi, Sravan ; Martin, Philippe

e15010 Background: Mecbotamab vedotin (BA3011) is antibody-drug conjugate (ADC) consisting of a conditionally active biologic (CAB) anti-AXL humanized (IgG1) monoclonal antibody conjugated to monomethyl auristatin E (MMAE) using a cleavable linker. BA3011 is being developed for the treatment patients with advanced solid tumors including sarcoma with AXL expression. Methods: As of data cutoff date 19 April 2022, BA3011 was administered by intravenous infusion to 67 patients, with doses ranged from 0.3 to 3 mg/kg once every three weeks (Q3W), 1.2 to 1.8 mg/kg once every two weeks (Q2W) and 1.8 mg/kg twice every three weeks (2Q3W). Population pharmacokinetics (popPK) analysis was performed using sequential modeling approach, where a PK model was first developed for BA3011 ADC alone, and then an integrated model was developed for BA3011 ADC and MMAE. The popPK base model for BA3011 ADC and MMAE was used to generate empirical Bayes estimates of PK parameters for patients in Study BA3011-001 and used for the exposure-response (E-R) safety analysis. E-R time-to-event models were developed to characterize the relationship between BA3011 ADC or MMAE exposure and the time to first incidence of adverse events (AEs). Results: A popPK model with two-compartment disposition and parallel linear and nonlinear elimination of BA3011 ADC, formation of MMAE from ADC, and two-compartment disposition and linear elimination of MMAE, adequately described the PK profiles of BA3011 ADC and MMAE in patients based on model evaluation using prediction-corrected visual predictive checks. Key PK parameter estimates are summarized in the table below. In the E-R safety analysis, statistically significant correlations were demonstrated between BA3011 ADC exposure and all safety endpoints explored (TEAE Grade ≥3, neutropenia Grade ≥3, increase in AST or ALT Grade ≥1, anemia Grade ≥2, and peripheral neuropathy Grade ≥1). Correlations were statistically significant between MMAE exposure and TEAE Grade ≥3, neutropenia Grade ≥3, increase in AST or ALT Grade ≥1, but not anemia Grade ≥2 or peripheral neuropathy Grade ≥1. Time-varying Cmax was selected as the most appropriate exposure metric for each model developed, calculated over the past 24 hours, 1 week, or 3 weeks, depending on the model. Conclusions: The popPK relationship between ADC and MMAE were adequately characterized using a sequential modeling approach. BA3011 ADC exposure was correlated with all safety endpoints evaluated whereas MMAE exposure did not demonstrate correlations with anemia or peripheral neuropathy. These models are essential to generate predictions of exposure and safety for dosing regimens to be evaluated in a planned Phase 2 clinical trial. Clinical trial information: NCT03425279 . [Table: see text]

04 Apr 2023·Cancer Research

Abstract 6335: Developing anti-IL-22 therapeutics for inflammation and cancer

Author: Boyle, William J. ; Joyner, Solmarie ; Wheeler, Christina ; Short, Jay M. ; Liu, Haizhen ; Frey, Gerhard ; Zhou, Wei ; Wang, Jing ; Chen, Jian ; Woodard, Kathryn ; Chang, Cathy

AbstractChronic inflammation facilitates the development of cancer, age-related, inflammatory autoimmune and other diseases. Proinflammatory cytokines play a central role in this pathogenic process by driving activation of NF-ƙB, STAT3 and other signaling cascades. IL-22 is an inflammatory cytokine involved in the pathology of autoimmune diseases such as psoriasis, atopic dermatitis, and ulcerative colitis. IL-22 has also been shown to promote epithelial cell proliferation, stemness and tumorigenesis in cancer. Recent studies demonstrated that neutralization of IL-22 reduced dysplasia and tumor development in preclinical models. To date, there has not been a clear application for anti-IL-22 therapy for autoimmune diseases and cancer, likely due to identifying the right disease indication and to their low potency and low efficacy. Thus, there remains an opportunity to explore the potential of more potent anti-IL-22 therapeutics. Using BioAtla’s proprietary antibody discovery and engineering platforms, we have generated humanized anti-IL-22 antibodies with high affinities to human, cynomolgus and mouse IL-22. In vitro data demonstrated that our anti-IL-22 antibodies inhibited IL-22-induced p-STAT3, CXCL-1 and IL-10 activities. In addition, our antibodies showed a 10-fold increased binding activity to human IL-22 compared to Fezakinumab, which was previously developed by Pfizer for the treatment of autoimmune diseases. BioAtla’s high affinity anti-IL-22 antibodies were shown to be more potent relative to Fezakinumab using multiple in vitro assays. To test the functions of our antibodies in vivo, we also established mouse models to determine anti-IL22 efficacy. More specifically, to study whether targeting IL-22 in an inflammation-induced tumor microenvironment reduces tumor occurrence, we developed an inflammation-driven sporadic colitis-associated colorectal cancer mouse model for ongoing cancer studies that will be discussed. In addition, we evaluated our anti-IL22 antibodies in an imiquimod-induced psoriasiform skin inflammation mouse model. The mice treated with potent anti-IL-22 antibodies had significantly reduced skin lesions, including erythema, scales, and skin thickness compared to isotype antibody-treated mice. Q-PCR analysis of the mouse skin demonstrated that treatment with our anti-IL-22 antibody led to significantly decreased RNA levels of the imiquimod-induced inflammatory marker CXCL3. Thus, the enhanced anti-IL-22 therapy is a promising strategy for targeting anti-inflammation in autoimmune diseases, such as psoriasis and atopic dermatitis, and inflammatory cancers, including colorectal cancer. In conclusion, the development of a potent, species cross reactive anti-IL-22 antibody using BioAtla’s antibody discovery and engineering platforms addresses the challenges of anti-IL-22 therapeutics and allows for translational studies in relevant animal efficacy and safety models.Citation Format: Christina Wheeler, Jian Chen, Cathy Chang, Gerhard Frey, Haizhen Liu, Jing Wang, Kathryn Woodard, Solmarie Joyner, Wei Zhou, William J. Boyle, Jay M. Short. Developing anti-IL-22 therapeutics for inflammation and cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6335.

News (Medical) associated with BioAtla, Inc.

04 Oct 2024

·www.globenewswire.com

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Title: Updated results from a phase 1 study of evalstotug (BA3071), an anti-CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumorsAuthors: Jacob Thomas, Eva Selfridge, Costantine Albany, Matthew H. Taylor, Inderjit Mehmi, Vineet Kwatra, Siwen Hu-Lieskovan, Paul De Souza, Ankit Mangla, Judith Llorin-Sangalang, Kartik Aysola, Omid HamidAbstract Number: 497Date & Time: Friday, November 8, 2024, 9:00a CDTLocation: Exhibit Halls AB A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded. About BioAtla®, Inc. BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com. Internal Contact:Richard WaldronChief Financial OfficerBioAtla, Inc.rwaldron@bioatla.com 858.356.8945 External Contact:Bruce MackleLifeSci Advisors, LLCbmackle@lifesciadvisors.com

Phase 1ImmunotherapyADCPhase 2

01 Oct 2024

·www.globenewswire.com

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced acceptance of an abstract for oral presentation at the upcoming Society for Melanoma Research 21st International Congress (SMR), being held from October 10–13, 2024, in New Orleans, LA. Oral Presentation Details: Abstract title:Evalstotug (BA3071): a potent conditionally active biologic (CAB) anti-CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicityPresenting Author:William Boyle, Ph.D.Abstract Type:OralSession Category:Developmental ImmunotherapyDate & Time: Friday, October 11th, 2024 from 8:00am–10:20am CDT The accepted abstract will be published in the 2024 SMR Abstract book in electronic format, as well as published online in the PCMR journal at www.wiley.com. Additionally, a copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded. About BioAtla®, Inc. BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com. Internal Contact:Richard WaldronChief Financial OfficerBioAtla, Inc.rwaldron@bioatla.com 858.356.8945 External Contact:Bruce MackleLifeSci Advisors, LLCbmackle@lifesciadvisors.com

Phase 1Phase 2ImmunotherapyADC

26 Sep 2024

·www.businesswire.com

Immuno-Oncology Therapeutics Forecasts to 2027: The Race for the Cures - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. CAR-T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out to 2027. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. Make investment decisions and valuations with confidence using the latest data. This report explores the opportunity in this market and what companies are poised to benefit. Key Topics Covered: 1 Market Guides 1.1 Situation Analysis 1.2 Guide for Executives and Marketing Staff 1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition 2.1 What is Cancer Immunotherapy? 2.2 Immunotherapy - the looming cures 2.3 Market Definition 2.4 Methodology 2.5 U.S. Medical Market and Pharmaceutical Spending - Perspective 2.5.1 Global Expenditures for Medicines 3 Immunotherapy - Guide to Immune Technologies 3.1 The Immune System 3.1.1 Innate immune system 3.1.2 Adaptive immune system 3.1.3 Tumor immunology - the immune surveillance system 3.2 Immuno Oncology Technologies 3.2.1 Monoclonal Antibodies 3.2.2 Cancer vaccines 3.2.3 Cytokines 3.2.4 Cell Based Therapies 3.2.5 Inhibitors/Agonists 3.2.6 Antibody Drug Conjugates 3.2.7 Others 4 Industry Overview 4.1 Market Players - Roles & Impacts 4.1.1 Drug manufacturers - Larger/pharmaceutical 4.1.2 Drug manufacturers - Generic 4.1.3 Contract Research and Manufacturing 4.1.4 In Vitro Diagnostics Industry 4.1.5 Drug Marketing Companies 4.1.6 Biotechnology Companies 4.1.7 Regulatory Bodies 5 Market Trends 5.1 Factors Driving Growth 5.1.1 Outcome potential 5.1.2 Fast tracking 5.1.3 Funding 5.1.4 Technology Environment 5.1.5 Target Solutions 5.2 Factors Limiting Growth 5.2.1 Cost of Treatment 5.2.2 Clinical Trials Role 5.2.3 Combinations 5.2.4 Protocols 5.3 Therapeutic Technology Development 5.3.1 Combinations - Issues and Complexity 5.3.2 Preference for a drug 5.3.3 Problems of Immunity Engineering 5.3.4 The Role of Cost 5.3.5 The Disruption Dynamic 5.3.6 CAR-T Cell Therapy 5.3.7 The Next Five Years 6 Cancer Immunotherapy Recent Developments 6.1 Recent Developments - Importance and How to Use This Section 6.2 Continued Success with Immunotherapy in Melanoma 6.3 AC Immune Receives FDA Fast Track Designation 6.4 LTZ Announces Financing 6.5 Immunotherapy for Cancer Overview 6.6 Implantable device shrinks pancreatic tumors 6.7 mRNA Vaccine And Immunotherapy Reduce Melanoma Recurrence 6.8 Towards a Universal Cancer Immunotherapy 6.9 New Strategy May Improve T-Cell Therapy in Solid Tumors 6.10 Immunotherapy linked to increase in Medicare spending 6.11 Immunotherapy Effective with Ovarian Cancer 6.12 Cancer Immunotherapy Granted Fast Track 7 Profiles of Key Immunotherapy Companies AbbVie Achilles Therapeutics Acumen Pharmaceuticals Adagene Adaptimmune Therapeutics Adicet Bio ALX Oncology Holdings Ambrx Biopharma Amgen Apexigen Arcus Biosciences argenx AstraZeneca Atreca Avalo Therapeutics Avid Bioservices Bavarian Nordic BioAtla Biogen Inc. BioNTech Bolt Biotherapeutics Bristol-Myers Squibb Candel Therapeutics Caribou Biosciences Celldex Therapeutics Checkpoint Therapeutics Chinook Therapeutics Corvus Pharmaceuticals Cullinan Oncology Eli Lilly EOM Pharmaceuticals Evaxion Biotech Genenta Science Gilead Sciences Gracell Biotechnologies Greenwich LifeSciences Gritstone bio Harpoon Therapeutics ImmunityBio Immunocore Holdings Immunome IMV Inc Incyte Indaptus Therapeutics Instil Bio Iovance Biotherapeutics Johnson & Johnson Marker Therapeutics Medicenna Therapeutics Merck & Co. Merus Moderna Mustang Bio Nanobiotix Neoleukin Therapeutics Novartis Novavax Oncorus PDS Biotechnology Pfizer Regeneron Pharmaceuticals Roche Sanofi Sensei Biotherapeutics Senti Biosciences Surface Oncology Takeda Pharmaceutical TC Biopharm ThermoGenesis Holdings UroGen Pharma Werewolf Therapeutics Xilio Therapeutics Zymeworks 8 The Global Market for Immuno-Oncology Therapeutics 8.1 Global Market Overview by Country 8.2 Global Market by Therapy 8.3 Global Market by Cancer 8.4 Global Market by Customer 9 Global Immuno-Oncology Therapy Markets - By Therapy 9.1 MAB 9.2 Cytokine 9.3 Vaccine 9.4 Cell Based 9.5 Inhibitor/Agonist 9.6 Other IO Therapy 10 Global Immuno-Oncology Therapeutic Markets - By Cancer 10.1 Breast 10.2 ColoRectal 10.3 Cervical 10.4 Lung 10.5 Precancer 10.6 Prostate 10.7 Melanoma 10.8 Blood 10.9 Other Cancer 11 Global Immuno-Oncology Therapeutic Markets - By Customer 11.1 Pharma 11.2 Clinic 11.3 Other Customer For more information about this report visit https://www.researchandmarkets.com/r/8355qg About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ImmunotherapyFast TrackASCO

100 Deals associated with BioAtla, Inc.

100 Translational Medicine associated with BioAtla, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

IND Approval

Phase 1 Clinical

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Ozuriftamab vedotin ( ROR2 x Tubulin )	Recurrent Squamous Cell Carcinoma of the Head and Neck More	Phase 2
Evalstotug ( CTLA4 )	Non-Small Cell Lung Cancer More	Phase 2
Mecbotamab vedotin ( AXL x Tubulin )	metastatic non-small cell lung cancer More	Phase 2
BA-3182 ( CD3 x EpCAM )	Advanced Lung Adenocarcinoma More	Phase 1
Ozuriftamab ( ROR2 )	Neoplasms More	Clinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis